(Q44597458)

4 December 2017

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias (English)

1 reference

4 December 2017

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias (English)

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

14 March 2024

0 references

1 reference

1 reference

Belen Ferrer

1

1 reference

4 December 2017

Nick Asbrock

2

1 reference

4 December 2017

Satish Kathuria

3

1 reference

4 December 2017

Daniele Piomelli

4

1 reference

4 December 2017

Andrea Giuffrida

5

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

https://escholarship.org/content/qt9jz0q6hw/qt9jz0q6hw.pdf?t=ovgapy

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511339

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1460-9568.2003.02896.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1460-9568.2003.02896.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

European Journal of Neuroscience

14 March 2024

published in

1 reference

4 December 2017

18

1 reference

4 December 2017

1607-1614

1 reference

4 December 2017

6

1 reference

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

4 December 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

CB1 cannabinoid receptor signalling in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Acetylcholine-mediated modulation of striatal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Formation and inactivation of endogenous cannabinoid anandamide in central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Different neuronal location of [3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

A second endogenous cannabinoid that modulates long-term potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2003.02896.X

The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor

14 March 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats

14 March 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

PET studies and motor complications in Parkinson's disease

14 March 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Electrophysiology of dopamine in normal and denervated striatal neurons

14 March 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

14 March 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications

14 March 2024

15

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor

14 March 2024

17

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization

14 March 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

14 March 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

The role of phosphorylation/dephosphorylation in agonist-induced desensitization of D1 dopamine receptor function: evidence for a novel pathway for receptor dephosphorylation.

14 March 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum

14 March 2024

25

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Postsynaptic endocannabinoid release is critical to long-term depression in the striatum

14 March 2024

26

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia

14 March 2024

27

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Molecular effects of dopamine on striatal-projection pathways

14 March 2024

28

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Turning off cortical ensembles stops striatal Up states and elicits phase perturbations in cortical and striatal slow oscillations in rat in vivo.

14 March 2024

29

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.

14 March 2024

30

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.

14 March 2024

34

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

The basal ganglia and adaptive motor control

14 March 2024

36

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis

14 March 2024

37

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.

14 March 2024

38

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Cannabinoid receptor localization in brain

14 March 2024

40

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Metabolic effects of nigrostriatal denervation in basal ganglia.

14 March 2024

42

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.

14 March 2024

45

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity

14 March 2024

48

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

14 March 2024

49

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine

14 March 2024

51

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury.

14 March 2024

57

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Levodopa motor complications in Parkinson's disease

14 March 2024

58

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Dye coupling between rat striatal neurons recorded in vivo: compartmental organization and modulation by dopamine.

14 March 2024

59

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats

14 March 2024

61

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons

14 March 2024

62

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain

14 March 2024

66

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease

14 March 2024

69

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Effect of dopamine system activation on substantia nigra pars reticulata output neurons: variable single-unit responses in normal rats and inhibition in 6-hydroxydopamine-lesioned rats.

14 March 2024

73

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats

14 March 2024

75

1 reference

https://api.crossref.org/works/10.1046/J.1460-9568.2003.02896.X

14 March 2024

Identifiers

1 reference

4 December 2017

1 reference